News | December 03, 2025
Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Now a test that offers new precision in prostate cancer detection
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Patients can now get the starting 2.5 mg dose for $299 per month
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
Subscribe To Our Newsletter & Stay Updated
